Investigational Farnesoid X Receptor Agonist Gets Fast Track Status for NASH
The FDA has granted Fast Track designation to TERN-101 (Terns Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.
All articles by Brian Park, PharmD
Next post in Liver
